Considering that we have tried three putative inhibitors of IGF-1R in this article and in our previous article and we have found that two of these inhibitors induced cell death (PPP and BMS) and blocked cell cycle in the G2 + M phase, but the mechanisms of cell death induction are different between them (one is caspase dependent, while the other one is caspase independent), our results suggest that by studying the differences between cell death mechanisms induced by BMS and PPP we have a new putative source to identify new therapeutically approaches for these types of poor diagnosis cancers. The gene discussed is IGF1R; the disease is cancer.